[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (24,976)

Search Parameters:
Keywords = target therapy

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
24 pages, 2099 KiB  
Article
Unveiling the Mechanisms of a Remission in Major Depressive Disorder (MDD)-like Syndrome: The Role of Hippocampal Palmitoyltransferase Expression and Stress Susceptibility
by Careen A. Schroeter, Anna Gorlova, Michael Sicker, Aleksei Umriukhin, Alisa Burova, Boris Shulgin, Sergey Morozov, Joao P. Costa-Nunes and Tatyana Strekalova
Biomolecules 2025, 15(1), 67; https://doi.org/10.3390/biom15010067 (registering DOI) - 5 Jan 2025
Abstract
Post-translational modifications of proteins via palmitoylation, a thioester linkage of a 16-carbon fatty acid to a cysteine residue, reversibly increases their affinity for cholesterol-rich lipid rafts in membranes, changing their function. Little is known about how altered palmitoylation affects function at the systemic [...] Read more.
Post-translational modifications of proteins via palmitoylation, a thioester linkage of a 16-carbon fatty acid to a cysteine residue, reversibly increases their affinity for cholesterol-rich lipid rafts in membranes, changing their function. Little is known about how altered palmitoylation affects function at the systemic level and contributes to CNS pathology. However, recent studies suggested a role for the downregulation of palmitoyl acetyltransferase (DHHC) 21 gene expression in the development of Major Depressive Disorder (MDD)-like syndrome. Here, we sought to investigate how susceptibility (sucrose preference below 65%) or resilience (sucrose preference > 65%) to stress-induced anhedonia affects DHHC gene expression in the hippocampus of C57BL/6J mice during the phase of spontaneous recovery from anhedonia. Because MDD is a recurrent disorder, it is important to understand the molecular mechanisms underlying not only the symptomatic phase of the disease but also a state of temporary remission. Indeed, molecular changes associated with the application of pharmacotherapy at the remission stage are currently not well understood. Therefore, we used a mouse model of chronic stress to address these questions. The stress protocol consisted of rat exposure, social defeat, restraint stress, and tail suspension. Mice from the stress group were not treated, received imipramine via drinking water (7 mg/kg/day), or received intraperitoneal injections of dicholine succinate (DS; 25 mg/kg/day) starting 7 days prior to stress and continuing during a 14-day stress procedure. Controls were either untreated or treated with either of the two drugs. At the 1st after-stress week, sucrose preference, forced swim, novel cage, and fear-conditioning tests were carried out; the sucrose test and 5-day Morris water maze test followed by a sacrifice of mice on post-stress day 31 for all mice were performed. Transcriptome Illumina analysis of hippocampi was carried out. Using the RT-PCR, the hippocampal gene expression of Dhhc3, Dhhc7, Dhhc8, Dhhc13, Dhhc14, and Dhhc21 was studied. We found that chronic stress lowered sucrose preference in a subgroup of mice that also exhibited prolonged floating behavior, behavioral invigoration, and impaired contextual fear conditioning, while auditory conditioning was unaltered. At the remission phase, no changes in the sucrose test were found, and the acquisition of the Morris water maze was unchanged in all groups. In anhedonic, but not resilient animals, Dhhc8 expression was lowered, and the expression of Dhhc14 was increased. Antidepressant treatment with either drug partially preserved gene expression changes and behavioral abnormalities. Our data suggest that Dhhc8 and Dhhc14 are likely to be implicated in the mechanisms of depression at the remission stage, serving as targets for preventive therapy. Full article
(This article belongs to the Section Molecular Medicine)
33 pages, 2920 KiB  
Review
Self-Emulsifying Drug Delivery Systems (SEDDS): Transition from Liquid to Solid—A Comprehensive Review of Formulation, Characterization, Applications, and Future Trends
by Prateek Uttreja, Indrajeet Karnik, Ahmed Adel Ali Youssef, Nagarjuna Narala, Rasha M. Elkanayati, Srikanth Baisa, Nouf D. Alshammari, Srikanth Banda, Sateesh Kumar Vemula and Michael A. Repka
Pharmaceutics 2025, 17(1), 63; https://doi.org/10.3390/pharmaceutics17010063 (registering DOI) - 5 Jan 2025
Abstract
Self-emulsifying drug delivery systems (SEDDS) represent an innovative approach to improving the solubility and bioavailability of poorly water-soluble drugs, addressing significant challenges associated with oral drug delivery. This review highlights the advancements and applications of SEDDS, including their transition from liquid to solid [...] Read more.
Self-emulsifying drug delivery systems (SEDDS) represent an innovative approach to improving the solubility and bioavailability of poorly water-soluble drugs, addressing significant challenges associated with oral drug delivery. This review highlights the advancements and applications of SEDDS, including their transition from liquid to solid forms, while addressing the formulation strategies, characterization techniques, and future prospects in pharmaceutical sciences. The review systematically analyzes existing studies on SEDDS, focusing on their classification into liquid and solid forms and their preparation methods, including spray drying, hot-melt extrusion, and adsorption onto carriers. Characterization techniques such as droplet size analysis, dissolution studies, and solid-state evaluations are detailed. Additionally, emerging trends, including 3D printing, hybrid systems, and supersaturable SEDDS (Su-SEDDS), are explored. Liquid SEDDS (L-SEDDS) enhance drug solubility and absorption by forming emulsions upon contact with gastrointestinal fluids. However, they suffer from stability and leakage issues. Transitioning to solid SEDDS (S-SEDDS) has resolved these limitations, offering enhanced stability, scalability, and patient compliance. Innovations such as personalized 3D-printed SEDDS, biologics delivery, and targeted systems demonstrate their potential for diverse therapeutic applications. Computational modeling and in silico approaches further accelerate formulation optimization. SEDDS have revolutionized drug delivery by improving bioavailability and enabling precise, patient-centric therapies. While challenges such as scalability and excipient toxicity persist, emerging technologies and multidisciplinary collaborations are paving the way for next-generation SEDDS. Their adaptability and potential for personalized medicine solidify their role as a cornerstone in modern pharmaceutical development. Full article
(This article belongs to the Special Issue Microemulsion Utility in Pharmaceuticals)
Show Figures

Figure 1

Figure 1
<p>Biopharmaceutics classification system.</p>
Full article ">Figure 2
<p>Mechanisms of drug absorption and bioavailability enhancement by SEDDS.</p>
Full article ">Figure 3
<p>Transformation of liquid SEDDS to solid SEDDS using various techniques.</p>
Full article ">Figure 4
<p>Key techniques for the characterization and evaluation of SEDDS formulations.</p>
Full article ">Figure 5
<p>Schematic representation of a self-double-emulsifying drug delivery system.</p>
Full article ">Figure 6
<p>Emerging trends in SEDDS innovation: exploring personalized medicine, in silico design, biologics delivery, hybrid systems, supersaturable SEDDS, and targeted-responsive formulations.</p>
Full article ">
25 pages, 3942 KiB  
Review
Pathophysiology and Management Strategies for Post-Stroke Spasticity: An Update Review
by Bei Chen, Tong Yang, Zi Liao, Feiyue Sun, Zhigang Mei and Wenli Zhang
Int. J. Mol. Sci. 2025, 26(1), 406; https://doi.org/10.3390/ijms26010406 (registering DOI) - 5 Jan 2025
Abstract
Post-stroke spasticity (PSS), characterized by a velocity-dependent increase in muscle tone and exaggerated reflexes, affects a significant portion of stroke patients and presents a substantial obstacle to post-stroke rehabilitation. Effective management and treatment for PSS remains a significant clinical challenge in the interdisciplinary [...] Read more.
Post-stroke spasticity (PSS), characterized by a velocity-dependent increase in muscle tone and exaggerated reflexes, affects a significant portion of stroke patients and presents a substantial obstacle to post-stroke rehabilitation. Effective management and treatment for PSS remains a significant clinical challenge in the interdisciplinary aspect depending on the understanding of its etiologies and pathophysiology. We systematically review the relevant literature and provide the main pathogenic hypotheses: alterations in the balance of excitatory and inhibitory inputs to the descending pathway or the spinal circuit, which are secondary to cortical and subcortical ischemic or hemorrhagic injury, lead to disinhibition of the stretch reflex and increased muscle tone. Prolongation of motoneuron responses to synaptic excitation by persistent inward currents and secondary changes in muscle contribute to hypertonia. The guidelines for PSS treatment advocate for a variety of therapeutic approaches, yet they are hindered by constraints such as dose-dependent adverse effects, high cost, and limited therapeutic efficacy. Taken together, we highlight key processes of PSS pathophysiology and summarize many interventions, including neuroprotective agents, gene therapy, targeted therapy, physiotherapy, NexTGen therapy and complementary and alternative medicine. We aim to confer additional clinical benefits to patients and lay the foundation for the development of new potential therapies against PSS. Full article
(This article belongs to the Special Issue CNS Injuries: 2nd Edition)
Show Figures

Figure 1

Figure 1
<p>The anatomy of descending motor conduction pathways. The spinal cord, as the final common motor pathway, transmits signals between the brain and muscle. Spinal reflexes are coordinately controlled by peripheral afferents and central motor commands. (Red arrow): Afferent nerve; (Brown arrow): Efferent nerve.</p>
Full article ">Figure 2
<p>Flowchart of pathophysiological mechanisms underlying post-stroke spasticity. (<span class="html-fig-inline" id="ijms-26-00406-i001"><img alt="Ijms 26 00406 i001" src="/ijms/ijms-26-00406/article_deploy/html/images/ijms-26-00406-i001.png"/></span>): Increased; (<span class="html-fig-inline" id="ijms-26-00406-i002"><img alt="Ijms 26 00406 i002" src="/ijms/ijms-26-00406/article_deploy/html/images/ijms-26-00406-i002.png"/></span>): Decreased.</p>
Full article ">Figure 3
<p>Pathophysiology of post-stroke spasticity (PSS). A stroke on one hemisphere, resulting in damage to both the CST and CRST, causes a decrease in output signals. The cortico-medial reticulospinal tracts (RST) of the contralateral cerebral hemisphere exhibit increased excitability and lack inhibition from the dorsal RST of the ipsilateral side, resulting in hyperexcitability or spontaneous firing in spinal motor neurons. (+): Excitatory; (−): Inhibitory;(×): Impaired; (<span class="html-fig-inline" id="ijms-26-00406-i001"><img alt="Ijms 26 00406 i001" src="/ijms/ijms-26-00406/article_deploy/html/images/ijms-26-00406-i001.png"/></span>): Increased; (<span class="html-fig-inline" id="ijms-26-00406-i002"><img alt="Ijms 26 00406 i002" src="/ijms/ijms-26-00406/article_deploy/html/images/ijms-26-00406-i002.png"/></span>): Decreased.</p>
Full article ">
19 pages, 8234 KiB  
Article
Integrated Analysis of Single-Cell and Bulk RNA Data Reveals Complexity and Significance of the Melanoma Interactome
by Michael J. Diaz, Jasmine T. Tran, Arthur M. Samia, Mahtab Forouzandeh, Jane M. Grant-Kels and Marjorie E. Montanez-Wiscovich
Cancers 2025, 17(1), 148; https://doi.org/10.3390/cancers17010148 (registering DOI) - 5 Jan 2025
Abstract
Background: Despite significant strides in anti-melanoma therapies, resistance and recurrence remain major challenges. A deeper understanding of the underlying biology of these challenges is necessary for developing more effective treatment paradigms. Methods: Melanoma single-cell data were retrieved from the Broad Single Cell Portal [...] Read more.
Background: Despite significant strides in anti-melanoma therapies, resistance and recurrence remain major challenges. A deeper understanding of the underlying biology of these challenges is necessary for developing more effective treatment paradigms. Methods: Melanoma single-cell data were retrieved from the Broad Single Cell Portal (SCP11). High-dimensional weighted gene co-expression network analysis (hdWGCNA), CellChat, and ligand-receptor relative crosstalk (RC) scoring were employed to evaluate intercellular and intracellular signaling. The prognostic value of key regulatory genes was assessed via Kaplan-Meier (KM) survival analysis using the ‘SKCM-TCGA’ dataset. Results: Twenty-seven (27) gene co-expression modules were identified via hdWGCNA. Notable findings include NRAS Q61L melanomas being enriched for modules involving C19orf10 and ARF4, while BRAF V600E melanomas were enriched for modules involving ALAS1 and MYO1B. Additionally, CellChat analysis highlighted several dominant signaling pathways, namely MHC-II, CD99, and Collagen-receptor signaling, with numerous significant ligand-receptor interactions from melanocytes, including CD99-CD99 communications with cancer-associated fibroblasts, endothelial cells, NK cells, and T-cells. KM analysis revealed that higher expression of SELL, BTLA, IL2RG, PDGFA, CLDN11, ITGB3, and SPN improved overall survival, while higher FGF5 expression correlated with worse survival. Protein-protein interaction network analysis further indicated significant interconnectivity among the identified prognostic genes. Conclusion: Overall, these insights underscore critical immune interactions and potential therapeutic targets to combat melanoma resistance, paving the way for more personalized and effective treatment strategies. Full article
(This article belongs to the Collection Emerging Therapeutics in Advanced Melanoma)
32 pages, 1321 KiB  
Review
Shattering the Amyloid Illusion: The Microbial Enigma of Alzheimer’s Disease Pathogenesis—From Gut Microbiota and Viruses to Brain Biofilms
by Anna Onisiforou, Eleftheria G. Charalambous and Panos Zanos
Microorganisms 2025, 13(1), 90; https://doi.org/10.3390/microorganisms13010090 (registering DOI) - 5 Jan 2025
Abstract
For decades, Alzheimer’s Disease (AD) research has focused on the amyloid cascade hypothesis, which identifies amyloid-beta (Aβ) as the primary driver of the disease. However, the consistent failure of Aβ-targeted therapies to demonstrate efficacy, coupled with significant safety concerns, underscores the need to [...] Read more.
For decades, Alzheimer’s Disease (AD) research has focused on the amyloid cascade hypothesis, which identifies amyloid-beta (Aβ) as the primary driver of the disease. However, the consistent failure of Aβ-targeted therapies to demonstrate efficacy, coupled with significant safety concerns, underscores the need to rethink our approach to AD treatment. Emerging evidence points to microbial infections as environmental factors in AD pathoetiology. Although a definitive causal link remains unestablished, the collective evidence is compelling. This review explores unconventional perspectives and emerging paradigms regarding microbial involvement in AD pathogenesis, emphasizing the gut–brain axis, brain biofilms, the oral microbiome, and viral infections. Transgenic mouse models show that gut microbiota dysregulation precedes brain Aβ accumulation, emphasizing gut–brain signaling pathways. Viral infections like Herpes Simplex Virus Type 1 (HSV-1) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) may lead to AD by modulating host processes like the immune system. Aβ peptide’s antimicrobial function as a response to microbial infection might inadvertently promote AD. We discuss potential microbiome-based therapies as promising strategies for managing and potentially preventing AD progression. Fecal microbiota transplantation (FMT) restores gut microbial balance, reduces Aβ accumulation, and improves cognition in preclinical models. Probiotics and prebiotics reduce neuroinflammation and Aβ plaques, while antiviral therapies targeting HSV-1 and vaccines like the shingles vaccine show potential to mitigate AD pathology. Developing effective treatments requires standardized methods to identify and measure microbial infections in AD patients, enabling personalized therapies that address individual microbial contributions to AD pathogenesis. Further research is needed to clarify the interactions between microbes and Aβ, explore bacterial and viral interplay, and understand their broader effects on host processes to translate these insights into clinical interventions. Full article
(This article belongs to the Special Issue Latest Review Papers in Medical Microbiology 2024)
Show Figures

Figure 1

Figure 1
<p><b>Illustration of the multifaceted interactions between various microbial communities and AD pathogenesis.</b> Gut microbiome dysbiosis, with bacterial amyloids like curli produced by <span class="html-italic">Escherichia coli</span> and <span class="html-italic">Pseudomonas aeruginosa</span>, can travel to the brain via the bloodstream or vagus nerve, contributing to Aβ protein aggregation in the brain. Brain microbiota can also lead to the formation of amyloid-containing brain biofilms, further contributing to Aβ protein aggregation. Bacterial or viral infections in the brain activate microglia and trigger neuroinflammation, releasing pro-inflammatory cytokines that exacerbate AD pathology. Oral microbiome dysbiosis and periodontal disease also contribute to AD progression by promoting inflammation and possibly introducing pathogens into the brain.</p>
Full article ">Figure 2
<p><b>Illustration of personalized treatment approaches based on microbiome-based and antiviral therapies for AD.</b> The diagnostic protocol for pathobiome involves standardized methods to assess microbial infections in AD, including pathogen identification and drug susceptibility testing. Based on these diagnostic results, personalized treatment strategies can be developed. These include FMT from a healthy, non-cognitively-impaired individual to restore a balanced gut microbiome, the use of probiotics and prebiotics to introduce beneficial microbiota and support microflora health, and antiviral treatments targeting acute and chronic viral infections with considerations for safety and efficacy. These strategies aim to leverage the benefits of microbiome modulation to mitigate AD pathology.</p>
Full article ">
21 pages, 966 KiB  
Review
A Personalized Approach for Oligometastatic Prostate Cancer: Current Understanding and Future Directions
by Parissa Alerasool, Susu Zhou, Eric Miller, Jonathan Anker, Brandon Tsao, Natasha Kyprianou and Che-Kai Tsao
Cancers 2025, 17(1), 147; https://doi.org/10.3390/cancers17010147 (registering DOI) - 5 Jan 2025
Viewed by 94
Abstract
Oligometastatic prostate cancer (OMPC) represents an intermediate state in the progression from localized disease to widespread metastasis when the radiographically significant sites are limited in number and location. With no clear consensus on a definition, its diagnostic significance and associated optimal therapeutic approach [...] Read more.
Oligometastatic prostate cancer (OMPC) represents an intermediate state in the progression from localized disease to widespread metastasis when the radiographically significant sites are limited in number and location. With no clear consensus on a definition, its diagnostic significance and associated optimal therapeutic approach remain controversial, posing a significant challenge for clinicians. The current standard of care for metastatic disease is to start systemic therapy; however, active surveillance and targeted radiotherapy have become attractive options to mitigate the long-term effects of androgen deprivation therapy (ADT). Furthermore, evolving biomarker methodologies may further define optimal treatment selection. In this review, we summarize the current understanding that guides the treatment of OMPC, with a focus on how host response can be an important contributing factor. Evolving scientific understanding and clinical development will continue to shape the landscape of treatment strategies for this distinct disease state. Full article
Show Figures

Figure 1

Figure 1
<p>Metastatic niche and the seed and soil hypothesis of metastasis.</p>
Full article ">Figure 2
<p>Treatment strategies for OMPC. Abbreviation: ARPI = Androgen receptor pathway inhibitor; ADT = Androgen deprivation therapy; IMRT = Intensity-modulated radiotherapy; OMPC = Oligometastatic prostate cancer; SBRT = Stereotactic body radiotherapy.</p>
Full article ">
17 pages, 303 KiB  
Review
Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes
by David Sipos, Bence L. Raposa, Omar Freihat, Mihály Simon, Nejc Mekis, Patrizia Cornacchione and Árpád Kovács
Cancers 2025, 17(1), 146; https://doi.org/10.3390/cancers17010146 (registering DOI) - 5 Jan 2025
Viewed by 95
Abstract
Glioblastoma, the most common and aggressive primary brain tumor in adults, presents a formidable challenge due to its rapid progression, treatment resistance, and poor survival outcomes. Standard care typically involves maximal safe surgical resection, followed by fractionated external beam radiation therapy and concurrent [...] Read more.
Glioblastoma, the most common and aggressive primary brain tumor in adults, presents a formidable challenge due to its rapid progression, treatment resistance, and poor survival outcomes. Standard care typically involves maximal safe surgical resection, followed by fractionated external beam radiation therapy and concurrent temozolomide chemotherapy. Despite these interventions, median survival remains approximately 12–15 months, with a five-year survival rate below 10%. Prognosis is influenced by factors such as patient age, molecular characteristics, and the extent of resection. Patients with IDH-mutant tumors or methylated MGMT promoters generally have improved survival, while recurrent glioblastoma is associated with a median survival of only six months, as therapies in these cases are often palliative. Innovative treatments, including TTFields, add incremental survival benefits, extending median survival to around 20.9 months for eligible patients. Symptom management—addressing seizures, headaches, and neurological deficits—alongside psychological support for patients and caregivers is essential to enhance quality of life. Emerging targeted therapies and immunotherapies, though still limited in efficacy, show promise as part of an evolving treatment landscape. Continued research and clinical trials remain crucial to developing more effective treatments. This multidisciplinary approach, incorporating diagnostics, personalized therapy, and supportive care, aims to improve outcomes and provides a hopeful foundation for advancing glioblastoma management. Full article
(This article belongs to the Special Issue Outcomes in Glioblastoma Patients: From Diagnosis to Palliation)
19 pages, 708 KiB  
Review
Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias
by Pasquale Niscola, Valentina Gianfelici, Marco Giovannini, Daniela Piccioni, Carla Mazzone and Paolo de Fabritiis
Cancers 2025, 17(1), 142; https://doi.org/10.3390/cancers17010142 (registering DOI) - 4 Jan 2025
Viewed by 283
Abstract
Menin (MEN1) is a well-recognized powerful tumor promoter in acute leukemias (AL) with KMT2A rearrangements (KMT2Ar, also known as MLL) and mutant nucleophosmin 1 (NPM1m) acute myeloid leukemia (AML). MEN1 is essential for sustaining leukemic transformation due to its interaction with wild-type KMT2A [...] Read more.
Menin (MEN1) is a well-recognized powerful tumor promoter in acute leukemias (AL) with KMT2A rearrangements (KMT2Ar, also known as MLL) and mutant nucleophosmin 1 (NPM1m) acute myeloid leukemia (AML). MEN1 is essential for sustaining leukemic transformation due to its interaction with wild-type KMT2A and KMT2A fusion proteins, leading to the dysregulation of KMT2A target genes. MEN1 inhibitors (MIs), such as revumenib, ziftomenib, and other active small molecules, represent a promising new class of therapies currently under clinical development. By disrupting the MEN1-KMT2Ar complex, a group of proteins involved in chromatin remodeling, MIs induce apoptosis and differentiation AL expressing KMT2Ar or NPM1m AML. Phase I and II clinical trials have evaluated MIs as standalone treatments and combined them with other synergistic drugs, yielding promising results. These trials have demonstrated notable response rates with manageable toxicities. Among MIs, ziftomenib received orphan drug and breakthrough therapy designations from the European Medicines Agency in January 2024 and the Food and Drug Administration (FDA) in April 2024, respectively, for treating R/R patients with NPM1m AML. Additionally, in November 2024, the FDA approved revumenib for treating R/R patients with KMT2Ar-AL. This review focuses on the pathophysiology of MI-sensitive AL, primarily AML. It illustrates data from clinical trials and discusses the emergence of resistance mechanisms. In addition, we outline future directions for the use of MIs and emphasize the need for further research to fully realize the potential of these novel compounds, especially in the context of specific genetic subtypes of challenging AL. Full article
(This article belongs to the Section Cancer Therapy)
24 pages, 1467 KiB  
Review
The Emerging Role of Oyster Mushrooms as a Functional Food for Complementary Cancer Therapy
by Priya Lakshmi Sreedharan, Malu Kishorkumar, Elke Gabriel Neumann and Shyam S. Kurup
Foods 2025, 14(1), 128; https://doi.org/10.3390/foods14010128 (registering DOI) - 4 Jan 2025
Viewed by 519
Abstract
The importance of functional food’s role in human nutrition as well as in the prevention of diseases, especially the treatment of chronic diseases like cancer, is an innovative field of research. Based on the studies regarding the antioxidant potential of oyster mushroom extract, [...] Read more.
The importance of functional food’s role in human nutrition as well as in the prevention of diseases, especially the treatment of chronic diseases like cancer, is an innovative field of research. Based on the studies regarding the antioxidant potential of oyster mushroom extract, it is evident that it has anticancer properties. The current article reviews the health benefits of edible oyster-mushroom-derived bioactive compounds, and how they specifically activate or regulate the immune system by affecting the maturation, differentiation, and proliferation of immune cells, thereby inhibiting cancer cell metastasis and growth. Mushrooms show anticancer potential by regulating a single molecule of a specific signaling pathway or by having multiple targets in the same or different signaling pathways. In addition, the prebiotic effects of mushrooms could enhance quality of life during and after cancer therapy by recovering the intestinal microbiota. More clinical research on oyster mushrooms needs to be conducted, and future studies should investigate the preventive aspects, which aid in reducing the rate of cancer occurrence, and the positive impact in cancer patients to prove that oyster mushrooms are preventive as a functional food as well as a curing dietary supplement for cancer patients. Full article
Show Figures

Figure 1

Figure 1
<p>The bioactive compounds in the oyster mushroom <span class="html-italic">Pleurotus ostreatus</span> have several health benefits, making them vital in the functional food category; specifically, antioxidant, antineoplastic, antitumor, and immunomodulating activities make them an ideal adjuvant for cancer therapy.</p>
Full article ">Figure 2
<p>Diagrammatic illustration of the manufacturing process of oyster mushroom nutraceuticals.</p>
Full article ">Figure 3
<p>Mechanisms of action of anticancer activities by the bioactive components from <span class="html-italic">Pleurotus ostreatus</span>.</p>
Full article ">
9 pages, 1835 KiB  
Article
PTT-Mediated Inhibition of Cancer Proliferation and Tumor Progression by DARPin-Coated Gold Nanoparticles
by Galina M. Proshkina, Elena I. Shramova, Ekaterina V. Serova, Egor A. Myachev, Aziz B. Mirkasymov, Sergey M. Deyev and Alexander B. Kotlyar
J. Nanotheranostics 2025, 6(1), 2; https://doi.org/10.3390/jnt6010002 (registering DOI) - 4 Jan 2025
Viewed by 312
Abstract
Targeting HER2-positive cancer cells with precision therapies is a critical challenge in oncology. Here, we present a study on gold nanoparticles (AuNPs) conjugated with DARPin_9-29, a designed ankyrin repeat protein with high specificity and affinity for HER2 receptors. In this study, we investigate [...] Read more.
Targeting HER2-positive cancer cells with precision therapies is a critical challenge in oncology. Here, we present a study on gold nanoparticles (AuNPs) conjugated with DARPin_9-29, a designed ankyrin repeat protein with high specificity and affinity for HER2 receptors. In this study, we investigate the therapeutic potential of AuNP-DARPin_9-29 conjugates, which was synthesized and characterized by us earlier, for photothermal therapy (PTT). By combining AuNP-DARPin treatment with visible light illumination, we show selective inhibition of HER2-positive cancer cell proliferation and tumor progression in a murine model. The results highlight the effectiveness of AuNP-DARPin in disrupting cancer cell viability and reducing tumor growth, providing a cost-effective and targeted approach for combating HER2-positive cancers. Full article
Show Figures

Figure 1

Figure 1
<p>DARPin-AuNPs’ properties. Hydrodynamic size distributions (<b>A</b>) and zeta-potential measurements (<b>B</b>) of AuNPs (red curves) and DARPin-AuNPs (blue curves). No aggregation of the nanoparticle-DARPin conjugate occurred during the experiment.</p>
Full article ">Figure 2
<p>Binding of DARPin-AuNPs to cells: flow cytometry analysis. (<b>A</b>) Flow cytometry of HER2-positive, SKOV-3/NanoLuc cells. (<b>B</b>) Flow cytometry of HER2-negative BJ-5TA cells. Cells treated with FITC-stained DARPin-AuNP—green curves, treated with FITC-stained BSA-AuNP—blue curves, and non-treated (control) cells—red curves. The cells were labeled with the conjugates and measured as described in <a href="#sec2-jnt-06-00002" class="html-sec">Section 2</a>.</p>
Full article ">Figure 3
<p>Binding of DARPin-AuNPs to cells: confocal microscopy analysis. Confocal microscopy of SKOV-3/NanoLuc cells treated with DARPin-AuNPs-Cy3.5 (<b>A</b>,<b>C</b>) or BSA-AuNP-Cy3.5 (<b>B</b>). Merged images in blue/red fluorescence channels of SKOV-3/NanoLuc cells after 10 (<b>A</b>) or 30 min (<b>C</b>) incubation with the DARPin conjugate or 10 min incubation with the BSA conjugate (<b>B</b>). Image (<b>D</b>) represents cells in green/blue fluorescence channels treated with LysoTracker green after 30 min incubation with DARPin-AuNPs-Cy3.5. (<b>E</b>) is a merged image in red/green fluorescence channels of cells treated with DARPin-AuNPs-Cy3.5 and LysoTracker green. Nuclei are stained with Hoechst33342.</p>
Full article ">Figure 4
<p>In vitro cytotoxicity of DARPin-AuNPs. Light-induced cytotoxicity of DARPin-AuNPs on SKOV-3/NanoLuc cells (dark-blue columns) and BJ-5TA cells (magenta columns). Violet columns—light-induced cytotoxicity of BSA-AuNPs on SKOV-3/NanoLuc cells.</p>
Full article ">Figure 5
<p>In vivo therapeutic efficacy of DARPin-AuNPs combined with PTT. (<b>A</b>) In vivo imaging of mice bearing SKOV-3/NanoLuc tumors. Left panels: mice treated with DARPin-AuNPs and exposed to 532 nm laser light, as described in <a href="#sec2-jnt-06-00002" class="html-sec">Section 2</a>. Right panels: control group of mice, untreated with the conjugate and not illuminated. The images display subcutaneous xenografts from both groups at various time points. (<b>B</b>) Luminescence intensity of tumors and surrounding areas, quantified from 2D images shown in (<b>A</b>).</p>
Full article ">
14 pages, 1288 KiB  
Article
Brain-Homing Peptide Expression on the Membrane Enhances the Delivery of Exosomes to Neural Cells and Tissue
by Jonhoi Smith, Melvin Field and Kiminobu Sugaya
Neuroglia 2025, 6(1), 3; https://doi.org/10.3390/neuroglia6010003 (registering DOI) - 4 Jan 2025
Viewed by 97
Abstract
Background/Objectives: Glioblastoma (GBM), a highly aggressive grade IV astrocytoma, poses a major therapeutic challenge due to the resistance of cancer stem cells (CSCs) existing within its cell population to the conventional therapies. Recently, we reported that RNA interference targeting CSC protection mechanism significantly [...] Read more.
Background/Objectives: Glioblastoma (GBM), a highly aggressive grade IV astrocytoma, poses a major therapeutic challenge due to the resistance of cancer stem cells (CSCs) existing within its cell population to the conventional therapies. Recently, we reported that RNA interference targeting CSC protection mechanism significantly improved therapeutic efficacy. However, challenges remain, including limited transfection efficiency in neural cells and the difficulty of crossing the blood–brain barrier (BBB). Methods: In this study, we investigated the potential of exosome-mediated delivery of therapeutic cargo to GBM cells by engineering the exosomes to carry green fluorescent protein (GFP) and expressing brain-homing peptide (BHP) on their surface, which has high affinity to the neural cells. Results: We found that BHP-modified exosomes doubled GFP delivery efficacy from 20% to 40%, outperforming traditional transfection methods like lipofection in vitro. In vivo, BHP-modified exosomes demonstrated an ability to cross the BBB and targeted cargo delivery to brain regions following intranasal and subcutaneous administration. Conclusions: These results underscore the potential of engineered exosomes for efficient cargo delivery to enhance therapeutic efficacy against brain tumors and suggest novel avenues for delivering biomolecules to the brain in the treatment of neurological disorders. Full article
19 pages, 1049 KiB  
Review
LEAP2 in Physiology—A Narrative Review
by Oskar Sosinski, Ewa Pruszynska-Oszmalek, Natalia Leciejewska, Maciej Sassek and Pawel Antoni Kolodziejski
Int. J. Mol. Sci. 2025, 26(1), 377; https://doi.org/10.3390/ijms26010377 (registering DOI) - 4 Jan 2025
Viewed by 124
Abstract
Liver Enriched Antimicrobial Peptide 2 (LEAP2) is a fascinating peptide that has gained significant attention since its discovery in 2003. Initially identified as an antimicrobial peptide, LEAP2 has more recently been found to play a key role in the regulation of energy metabolism. [...] Read more.
Liver Enriched Antimicrobial Peptide 2 (LEAP2) is a fascinating peptide that has gained significant attention since its discovery in 2003. Initially identified as an antimicrobial peptide, LEAP2 has more recently been found to play a key role in the regulation of energy metabolism. One of the most notable functions of LEAP2 is its interaction with the ghrelin hormone, which is known for stimulating hunger. LEAP2 acts as an inhibitor of ghrelin, thereby reducing food intake and influencing energy balance. The physiological roles of LEAP2 extend beyond appetite suppression. Studies have shown that LEAP2 has an impact on insulin secretion, suggesting its potential involvement in glucose metabolism and possibly insulin sensitivity, which is crucial in managing conditions like type 2 diabetes. Moreover, LEAP2 levels appear to fluctuate based on factors such as gender, developmental stage, and even interventions like bariatric surgery, which is known for its role in managing obesity and diabetes. Given these findings, LEAP2 shows potential as a therapeutic target, particularly for addressing obesity and metabolic diseases such as type 2 diabetes. Its ability to influence food intake and energy balance makes it a promising candidate for further research into therapies aimed at weight regulation and glycemic control. In the future, LEAP2 could become an important agent in the development of treatments aimed at curbing obesity and its associated metabolic disorders. Full article
(This article belongs to the Section Molecular Biology)
17 pages, 3365 KiB  
Article
Circulating T Cell Subsets in Type 1 Diabetes
by Aldo Ferreira-Hermosillo, Paola Santana-Sánchez, Ricardo Vaquero-García, Manuel R. García-Sáenz, Angélica Castro-Ríos, Adriana K. Chávez-Rueda, Rita A. Gómez-Díaz, Luis Chávez-Sánchez and María V. Legorreta-Haquet
Cells 2025, 14(1), 48; https://doi.org/10.3390/cells14010048 (registering DOI) - 4 Jan 2025
Viewed by 203
Abstract
Type 1 diabetes (T1D) is a complex disease driven by the immune system attacking the insulin-producing beta cells in the pancreas. Understanding the role of different T cell subpopulations in the development and progression of T1D is crucial. By employing flow cytometry to [...] Read more.
Type 1 diabetes (T1D) is a complex disease driven by the immune system attacking the insulin-producing beta cells in the pancreas. Understanding the role of different T cell subpopulations in the development and progression of T1D is crucial. By employing flow cytometry to compare the characteristics of T cells, we can pinpoint potential indicators of treatment response or therapeutic inefficacy. Our study reveals elevated prolactin (PRL) levels in T1D patients, along with a decreased production of key cytokines. Additionally, PD1 appears to play a significant role in T1D. Notably, PRL levels correlate with an earlier disease onset and a specific T cell phenotype, hinting at the potential influence of PRL. These findings highlight the need for further research to identify promising cellular targets for more effective and tailored therapies. Full article
(This article belongs to the Special Issue Cellular and Molecular Mechanisms in Immune Regulation)
Show Figures

Figure 1

Figure 1
<p>Serum levels of prolactin, glucose, and glycosylated hemoglobin. Quantification of serum levels of PRL glucose and HbA1 were compared between the patients with T1D and healthy controls. The results indicated significantly increased expression of (<b>a</b>) PRL (<span class="html-italic">p</span> = 0.007), (<b>b</b>) Glucose (<span class="html-italic">p</span> &lt; 0.014), and (<b>c</b>) HbA1c (<span class="html-italic">p</span> &lt; 0.0001) in T1D patients compared to healthy controls. Data are presented as mean ± standard division (SD). (Healthy controls, n = 29, PE women, n = 28). <span class="html-italic">p</span> &lt; 0.05 is considered statistically significant (** <span class="html-italic">p</span> ≤ 0.01, **** <span class="html-italic">p</span> ≤ 0.0001).</p>
Full article ">Figure 2
<p>Serum levels of cytokines. Quantification of cytokine serum levels using flow cytometry. Serum cytokine levels were compared between patients with T1D and healthy controls. The results showed significantly increased expression of (<b>a</b>) IL-17 (<span class="html-italic">p</span> = 0.028), (<b>b</b>) Perforin (<span class="html-italic">p</span> &lt; 0.028), and (<b>c</b>) Granulysin (<span class="html-italic">p</span> &lt; 0.008) in healthy controls compared to T1D patients. Data is presented as mean ± standard deviation (SD). (Healthy controls, n = 29; T1D patients, n = 28). <span class="html-italic">p</span> &lt; 0.05 was considered statistically significant (* <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01).</p>
Full article ">Figure 3
<p>Circulating T cells. (<b>a</b>) Flow cytometry analysis strategy to gate on T cells. FSC-H vs. FSC-A plot was used to exclude doublets; lymphocytes were gated on the FSC-A vs. SSC-A plot, and live cells were gated in the Ghost Dye negative (Viability) and CD3-BV650+. From living T cells, we selected the CD4+ or CD8+ gate, and using the pre-designed panels from each T cell subtype, we selected the following markers: (<b>b</b>) Exhausted T cells (CD4+TIGIT+PD1+LAG3+CTLA-4+ or CD8+TIGIT+PD1+LAG3+CTLA-4+). (<b>c</b>) Follicular T cells (CD4+CXCR5+PD1+ICOS+ or CD8+CXCR5+PD1+ICOS+) (<b>d</b>) Memory T cells (CD4+CD45RO± CCR7± or CD8+CD45RO±CCR7±).</p>
Full article ">Figure 4
<p><b>Comparison of frequencies of CD4/CD8 among live CD3+.</b> (<b>a</b>–<b>d</b>) follicular T (CD4+CXCR5+PD1+ICOS+ or CD8+CXCR5+PD1+ICOS+), and (<b>e</b>–<b>h</b>) exhausted T (CD4+TIGIT+ PD1+LAG3+CTLA-4+ or CD8+TIGIT+PD1+ LAG3+CTLA-4+). These are shown as proportions or absolute numbers of circulating T cells in T1D and healthy controls. <span class="html-italic">p</span> &lt; 0.05 was considered statistically significant (**** <span class="html-italic">p</span> ≤ 0.0001).</p>
Full article ">Figure 5
<p>Comparison of the frequencies of CD4/CD8 among live CD3+ cells, TCD4+ or T CD8+. (<b>a</b>–<b>d</b>) effector memory (CD45RO+CCR7-), (<b>e</b>–<b>h</b>) central memory (CD4+CD45RO+CCR7+), (<b>i</b>–<b>l</b>) naive (CD45RO-CCR7+), and (<b>m</b>–<b>p</b>) effector (CD45RO-CCR7-) T cells are shown as proportions (left) or absolute numbers (right) of circulating T cells in T1D and healthy controls. <span class="html-italic">p</span> &lt; 0.05 was considered statistically significant (*** <span class="html-italic">p</span> ≤ 0.001).</p>
Full article ">Figure 6
<p><b>Comparison of frequencies of TCD4+ or T CD8+PD1+ between those of</b> (<b>a</b>,<b>b</b>) central memory (CD4+CD45RO+CCR7+), (<b>c</b>,<b>d</b>) effector memory (CD4+CD45RO+CCR7-), (<b>e</b>,<b>f</b>) effectors (CD45RO-CCR7-), and (<b>g</b>,<b>h</b>) naïve (CD45RO-CCR7+) are shown as the absolute number of circulating T cells in T1D and healthy controls. <span class="html-italic">p</span> &lt; 0.05 was considered statistically significant (* <span class="html-italic">p</span> ≤ 0.05, ** <span class="html-italic">p</span> ≤ 0.01).</p>
Full article ">Figure 7
<p><b>Two-way dispersion graph: prolactin and CD4 vs. TD1 diagnosis time</b> (<b>a</b>) Spearman’s correlations_ TD1 diagnosis time and prolactin levels: NP r = 0.3436, <span class="html-italic">p</span> = 0.050 *, HP r = −0.5667, ns. (<b>b</b>) TD1 diagnosis time and CD8-CM: NP r = −0.6355, <span class="html-italic">p</span> = 0.0026 *, HP r = 0.4857, ns. (<b>c</b>) TD1 diagnosis time and CD8-EM_PD1: NP r = −0.4075, ns HP r = 0.200, ns (<b>d</b>) TD1 diagnosis time and CD8_NAIVE: NP r = −0.4849, <span class="html-italic">p</span> = 0.0289 * HP r = 0.1429, ns. (<b>e</b>) TD1 diagnosis time and CD8_Exhausted: NP r = 0.500, <span class="html-italic">p</span> = 0.024 *. HP r = 0.200, ns. (<b>f</b>) TD1 diagnosis time and CD8_ThF = −0.7580, <span class="html-italic">p</span> = 0.0001 *. HP r = 0.2571, ns. HP = Hyperprolactin, NP = Normoprolactin.</p>
Full article ">
16 pages, 4927 KiB  
Article
Synergistic Antibacterial Action of Norfloxacin-Encapsulated G4 Hydrogels: The Role of Boronic Acid and Cyclodextrin
by Monica-Cornelia Sardaru, Irina Rosca, Simona Morariu, Elena-Laura Ursu and Alexandru Rotaru
Gels 2025, 11(1), 35; https://doi.org/10.3390/gels11010035 (registering DOI) - 4 Jan 2025
Viewed by 195
Abstract
In this present study, we developed and characterized a series of supramolecular G4 hydrogels by integrating β-cyclodextrin (β-CD) and boronic acid linkers into a supramolecular matrix to enhance antibacterial activity against Staphylococcus aureus (S. aureus). We systematically investigated [...] Read more.
In this present study, we developed and characterized a series of supramolecular G4 hydrogels by integrating β-cyclodextrin (β-CD) and boronic acid linkers into a supramolecular matrix to enhance antibacterial activity against Staphylococcus aureus (S. aureus). We systematically investigated how varying the number of free boronic acid moieties (ranging from two to six), along with guanosine and β-CD content, influences both the structural integrity and antimicrobial efficacy of these materials. Comprehensive characterization using FTIR, circular dichroism, X-ray diffraction, SEM, AFM, and rheological measurements confirmed successful synthesis and revealed that higher boronic acid content correlated with a stronger, more organized network. The most effective hydrogel displayed an inhibition zone of 25 mm in disk diffusion assays, and was further explored as a drug delivery platform, with the aim to exploit the capacity of the free β-CD cavity of the hydrogels to incorporate hydrophobic drugs. Norfloxacin (Nfx), a poorly water-soluble antibiotic, was successfully encapsulated within the hydrogel matrix through the inclusion of complex formation with β-CD, improving its solubility and enabling sustained, targeted release. The Nfx-loaded hydrogel expanded the inhibition zone to 49 mm and completely eradicated S. aureus cells within 24 h, outperforming both the unloaded hydrogel and free Nfx. These results highlight the synergistic effect of boronic acid moieties and controlled drug release, underlining the potential of these hydrogels as versatile platforms for localized antimicrobial therapy, such as in wound dressings or implant coatings. Nevertheless, further in vivo studies and long-term stability assessments are needed to fully establish clinical relevance, safety, and scalability before these systems can be translated into routine healthcare applications. Full article
(This article belongs to the Special Issue Customizing Hydrogels: A Journey from Concept to End-Use Properties)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>ATR-FTIR spectra for: (<b>a</b>) BdCD-G4_2 xerogel, and its precursors (<span class="html-italic">β</span>-CD, benzene-1,4-diboronic acid, and guanosine); (<b>b</b>) xerogels BdCD-G4_2-6.</p>
Full article ">Figure 2
<p>Representative SEM images for BdCD-G4_2 (<b>left</b>) and BdCD-G4_6 (<b>right</b>) xerogels (scale bar—20 µm).</p>
Full article ">Figure 3
<p>Examples of AFM images. (<b>a</b>) BdCD-G4_2: scale bar—4 µm (<b>left</b>), scale bar—1 µm (<b>middle</b>), Z-profiles along lines marked on images (<b>right</b>). (<b>b</b>) BdCD-G4_6: scale bar—4 µm (<b>left</b>), scale bar—1 µm (<b>middle</b>), Z-profiles along lines marked on images (<b>right</b>).</p>
Full article ">Figure 4
<p>Amplitude and frequency sweep tests for BdCD-G4_2-6 samples at 25 °C: (<b>a</b>) G’ and G” as function of τ at 10 rad·s<sup>–1</sup> and (<b>b</b>) variation in G’ and G” with ω at strain of 5%.</p>
Full article ">Figure 5
<p>In vitro antibacterial activity. (<b>a</b>) Growth inhibition of bacterial colonies expressed as percent of viable bacteria vs. incubation time, and (<b>b</b>) <span class="html-italic">S. aureu</span> colonies after 2–24 h of incubation with xerogels.</p>
Full article ">Scheme 1
<p>Schematic representation of BdCD-G4_2-6 hydrogel preparation; images of resulted self-standing transparent hydrogels.</p>
Full article ">Scheme 2
<p>Schematic representation for formation of 3:1 inclusion complex between <span class="html-italic">β</span>-CD and Nfx, followed by synthesis of Nfx-loaded hydrogel (BdCD-G4_2-Nfx).</p>
Full article ">
18 pages, 1833 KiB  
Article
NF-κB-Inducing Kinase Is Essential for Effective c-Rel Transactivation and Binding to the Il12b Promoter in Macrophages
by Natalia Cuesta, Anna D. Staniszewska, Cristóbal Moreno, Carmen Punzón and Manuel Fresno
Biology 2025, 14(1), 33; https://doi.org/10.3390/biology14010033 - 3 Jan 2025
Viewed by 265
Abstract
This study investigates the role of NIK in activating specific inflammatory genes in macrophages, focusing on the effect of a mutation in NIK found in alymphoplasia (aly/aly) mice. Mouse peritoneal macrophages from aly/aly mice showed a severe defect in the production [...] Read more.
This study investigates the role of NIK in activating specific inflammatory genes in macrophages, focusing on the effect of a mutation in NIK found in alymphoplasia (aly/aly) mice. Mouse peritoneal macrophages from aly/aly mice showed a severe defect in the production of some pro-inflammatory cytokines, such as IL-12. This effect seemed to take place at the transcriptional level, as shown by the reduced transcription of Il12b and Il12a in aly/aly macrophages after exposure to the TLR4 agonist LPS. Immunoprecipitation studies showed that the binding of NIK to c-Rel was not efficient in RAW 264.7 cells over-expressing the aly/aly mutation. In addition, the shuttling of c-Rel to the nucleus was shown to be impaired in aly/aly macrophages in response to LPS. When looking more specifically at the regulation of the Il12b promoter, we found that c-Rel bound to the NF-kB consensus sequence in macrophages from WT mice 1 hr. after LPS challenge, whereas in aly/aly macrophages, the transcription factor bound to the promoter was p65. These findings indicate that NIK is essential for efficient c-Rel activation and proper inflammatory responses. NIK dysfunction could lead to weakened immune responses, and targeting this pathway may help in developing therapies for immune-related conditions. Full article
(This article belongs to the Section Biochemistry and Molecular Biology)
Back to TopTop